Cubist Nears Goalpost Of Five Marketed Drugs In 2015
This article was originally published in The Pink Sheet Daily
The antibiotic developer is gearing up to launch two new products now that it has filed an NDA for the antibiotic ceftolozane/tazobactam with FDA April 21.
You may also be interested in...
Cubist will rely on its experience in infectious disease to drive growth of Dificid for Clostridium difficile infection and to launch tedizolid for skin infections, but the commercial market for new antibiotics is daunting and re-creating the success of Cubicin won’t be easy.
Cubist has focused on marketing its sole drug, Cubicin, since the antibiotic was approved in 2003, but through business development and clinical progress, the biopharma is in the midst of a transformation.
The company is seeking FDA accelerated approval of the closely watched gene therapy based on a surrogate marker and has proposed its fully enrolled Phase III trial to serve as a confirmatory study.